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Endometrial cancer is the most common gynecologic malig-
nancy among women in developed countries. Most are
diagnosed at stage I and their probability of surviving the
disease is excellent. Most women at diagnosis are older,
obese, and have multiple comorbidities. These factors need
to be considered when treating patients with this highly
curable disease. When recurrences occur at the vaginal apex,
almost 50% are salvaged with radiation therapy with or
without surgical excision. However, treatment of nodal or
distant recurrences or of advanced disease at diagnosis is
more challenging.
One of the challenges faced by those treating this disease
is how to identify those women who are at risk of having
occult metastatic disease at initial diagnosis and to provide
eﬀective adjuvant therapy that would prevent recurrences
in this select group of patients while minimizing therapy-
induced morbidity.
In this special issue on endometrial cancer, the authors
tackle some of these issues. The articles accurately and
succinctly summarize the current approach to the treatment
of this disease and looks at the future by discussing possible
novel interventions for the treatment of advanced or recur-
rent disease. The controversies in the surgical management
of endometrial cancer are discussed, as are the minimally
invasive surgical techniques.
The international group of authors and editors provide
a worldwide perspective about areas of agreement, topics of
controversies, and issues that need yet to be clearly deﬁned.
Authors from The Netherlands discuss the controversies
in evaluating women with postmenopausal bleeding. They
weight the convenience, but possible decreased accuracy, of
transvaginal ultrasound against the invasiveness of endome-
trial biopsy, hysteroscopy, and D&C. Another group from
The Netherlands, using their national pathology database,
demonstrates the prevalence of synchronous ovarian and
endometrialadenocarcinomas.AuthorsfromIndonesiathor-
oughly discuss the genetics of endometrial cancer, while
authors from Bologna, Italy address controversies in the
surgical treatment of endometrial carcinoma to include the
laparoscopic and robotic-assisted approaches. The group
fromtheUniversityofToyama,Japanpresentsaretrospective
analysis of 83 women with endometrial carcinoma who
by pre- and intraoperative assessment was considered to
be at low risk for recurrence. These women underwent
a total abdominal hysterectomy and bilateral salpingo-
oophorectomy without lymphadenectomy. The authors
report a 98% 5-year survival. The authors from China
present a succinct but comprehensive review of endometrial
carcinoma, as do the group from the Catholic Univer-
sity of Sacred Heart in Rome and Temple University in
Philadelphia. The authors from the University of Texas in
San Antonio discuss the diﬀerences in the molecular proﬁle
of type I and type II endometrial carcinoma, as well as
the molecular changes observed in endometrial sarcomas.
The authors from Oita University, Japan; Utrecht, The
Netherlands; and the University of Florence, Italy discuss2 Obstetrics and Gynecology International
possible novel approaches to the treatment of advanced or
recurrent endometrial adenocarcinoma. And ﬁnally, authors
from Greece and the United Kingdom summarize the
evidence for adjuvant and molecularly targeted therapy of
endometrial cancer.
In this special issue of Obstetrics and Gynecology Inter-
national, the reader will conveniently ﬁnd a comprehensive
summary of the state-of-the-art diagnostic strategies, biol-
ogy, and evidence-based treatment of endometrial cancer
from an international perspective.
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